Company

Santa Ana Bio, Inc.

Santa Ana Bio develops targeted medicines for autoimmune and inflammatory diseases.

About

Founded in 2022 by Peter Emtage and based in Alameda, US, Santa Ana Bio develops medicines for autoimmune and inflammatory diseases. Its pipeline includes monoclonal and bispecific antibodies and antibody-drug conjugates, supported by a platform that combines patient data and antibody engineering. In June 2024, the company raised USD 125 million in Series B funding led by GV, with participation from RTW Investments, Access Industries, Andreessen Horowitz, Versant Ventures and Life Science Innovations. It planned to accelerate research and development.

2Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in